Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 3/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15665221 | 1.00 | SSTR4 (0.56) | SSTR4METAP2METAP1LMNAGAA | |
| SCHEMBL15665071 | 1.00 | SSTR4 (0.56) | SSTR4METAP2METAP1LMNAGAA | |
| SCHEMBL15665657 | 1.00 | SSTR4 (0.56) | SSTR4METAP2METAP1LMNAGAA | |
| SCHEMBL15665589 | 1.00 | SSTR4 (0.56) | SSTR4METAP2METAP1LMNAGAA | |
| SCHEMBL15665069 | 1.00 | SSTR4 (0.56) | SSTR4METAP2METAP1LMNAGAA | |
| SCHEMBL29494454 | 0.82 | — | — | |
| SCHEMBL15665088 | 0.80 | RECQL (0.61) | LMNAGAA | |
| SCHEMBL13105663 | 0.80 | RECQL (0.61) | LMNAGAA | |
| SCHEMBL15665087 | 0.80 | RECQL (0.61) | LMNAGAA | |
| SCHEMBL15665273 | 0.80 | RECQL (0.61) | LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140127762-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED PROLINE | API CORPORATION (JP) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127762-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED PROLINE | PREP, NPEPPS, DNPEP | SSTR4 621/4885METAP2 314/4885METAP1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.